Garuda - Garba Rujukan Digital

Scoping Review: Rasio Monosit Limfosit sebagai Penunjang untuk Menegakkan Diagnosis pada Penderita Tuberkulosis Algifari Fauzia; Purwitasari Purwitasari; Heni Muflihah
Jurnal Integrasi Kesehatan dan Sains Vol 3, No 2 (2021): Jurnal Integrasi Kesehatan dan Sains
Publisher : Universitas Islam Bandung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/jiks.v3i2.7501

Tuberkulosis (TB) merupakan penyakit yang disebabkan oleh Mycobacterium tuberculosis. Indonesia menempati urutan ketiga kasus TB terbanyak di dunia. Pemeriksaan bakteriologis menjadi standar untuk menegakkan diagnosis tuberkulosis. Keterbatasan pemeriksaan kultur bakteri adalah membutuhkan waktu yang lama, sedangkan pemeriksaan TCM tidak selalu menunjukkan bakteri masih hidup. Pemeriksaan imunologis interferon-γ release assays (IGRA) memiliki harga mahal dan membutuhkan alat khusus. Pemeriksaan hematologi rutin mudah dilakukan sehingga memiliki potensi menunjang penegakan diagnosis TB berdasar atas parameter imunologis. Tujuan penelitian ini adalah melakukan literature review untuk mengidentifikasi potensi rasio monosit limfosit (MLR) sebagai penunjang diagnosis TB. Pencarian artikel dilakukan secara online dari database Pubmed, Springer Link, dan Science Direct. Tahapan penyaringan artikel mengikuti alur PRISMA. Pada tahap akhir, artikel yang eligible dipilih berdasar atas kriteria patient, intervention, comparison, outcome, and study (PICOS), yaitu pasien TB, rasio monosit limfosit, diagnosis TB, dan original study. Hasil penelitian ini mendapatkan tujuh artikel dari jumlah awal 8.942 artikel yang ditemukan dari kata kunci. Dua dari tujuh artikel menyatakan MLR dapat menunjang diagnosis TB. Dua artikel menunjukkan monosit dan limfosit dapat menjadi penanda infeksi bakteri termasuk TB. Satu artikel menyatakan hubungan TB dengan penurunan produksi sitokin monosit dan limfosit. Dua artikel menyatakan MLR tidak ada hubungan dengan kasus TB. Terdapat satu artikel yang menyatakan batas nilai MLR 0,378 untuk menunjang diagnosis TB. Penelitian observasional tentang MLR untuk menunjang diagnosis TB di Indonesia masih perlu dilakukan terutama pengkajian batas nilai MLR. SCOPING REVIEW: MONOCYTE LYMPHOCYTE RATIO AS SUPPORT TO ENFORCE ON PATIENT TUBERCULOSISTuberculosis (TB) is a disease caused by Mycobacterium tuberculosis. Indonesia ranks third with the most TB cases in the world. A bacteriological examination is a standard for diagnosing TB. A bacteriological examination is a standard for establishing the diagnosis of tuberculosis. The limitation of bacterial culture examination is that it takes a long time, while TCM examination does not always show the bacteria are still alive. Interferon-γ release assays (IGRA) examinations are expensive and require special equipment. Routine hematology tests are easy to do so as they have the potential to support the diagnosis of TB based on immunological parameters. The purpose of this study was to conduct a literature review to identify the potential for monocyte lymphocyte ratio (MLR) to support the diagnosis of TB. Search for articles was conducted online from PubMed, Springer Link, and Science Direct databases. The steps of filtering articles follow the PRISMA flow. In the final stage, eligible articles were selected based on patient, intervention, comparison, outcome, and study (PICOS) criteria, namely TB patient, monocyte lymphocyte ratio, TB diagnosis, and the original research. The results of this study obtained seven articles from 8,942 articles found from keywords. Two of the seven articles said that MLR could support the diagnosis of TB. Two articles showed that monocytes and lymphocytes could be markers of bacterial infection include TB. One article said the association of TB with decreased production of monocyte and lymphocyte cytokines. Two articles said that MLR had no relationship with TB cases. There is one article that states the MLR value limit is 0.378 to support the diagnosis of TB. Observational research on MLR to support the diagnosis of TB in Indonesia still needs to be done, especially the assessment of the limit of the MLR value.

Tingkat Kepatuhan Pengobatan Pasien Fase Intensif Berdasarkan Karakteristik Pasien TB di Puskesmas Rancasalak Aini Agnia; Heni Muflihah
Jurnal Riset Kedokteran Volume 2, No.1, Juli 2022, Jurnal Riset Kedokteran (JRK)
Publisher : UPT Publikasi Ilmiah Unisba

Abstract. Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (M. tuberculosis). 2019, Indonesia is the second country with the highest TB cases in the world. One of the problems that threaten TB control is anti-tuberculosis drug resistanceNon-adherence in undergoing treatment is one of the factors that may increase resistance and ultimately reduce the success of TB treatment.This study aims to determine the level of adherence to the intensive phase of treatment based on the characteristics of TB patients at the Rancasalak Garut Health Center. This observational study useddata on the TB01 form. The research subjects were pulmonary tuberculosis patients at the Rancasalak Garut Health Center during the period January 2019-October 2022. Of 108 subjects, there were 88 people (81.48%) who adhered to treatment and 20 people (18.51%) who did not adhere to treatment. Patients who adhered to treatment had characterstics: 53 people (60.23%) were male86 people (97.73%) had constant weight, and had mean of age 37 years old. a study conducted by Heldiastri said that the level of treatment adherence was more in men, a study conducted by Friskilla that patients who were compliant in treatment were aged 25-49 years, and a study conducted by Farrah Bintang stated that in patients undergoing treatment TB obediently experienced improvements in measures of nutritional status. Abstrak. Tuberkulosis (TB) merupakan penyakit menular yang bisa disebabkan karena adanya infeksi bakteri Mycobacterium tuberculosis (M. tuberculosis). ada tahun 2019 Indonesia menjadi negara kedua dengan kasus TB tertinggi di dunia. Salah satu masalah yang mengancam pengendalian TB adalah resistensi obat anti TB (OAT). Ketidakpatuhan dalam menjalani pengobatan menjadi salah satu faktor yang dapat meningkatkan resistensi dan pada akhirnya dapat menurunkan keberhasilan pengobatan TB. Penelitian ini bertujuan untuk mengetahui tingkat kepatuhan pengobatan fase intensif berdasarkan karakteristik pasien TB di Puskesmas Rancasalak Garut. Penelitian observasi analitik ini menggunakan pendekatan cross-sectional menggunakan data pada formulir TB01. Subjek penelitian adalah pasien TB paru di Puskesmas Rancasalak Garut periode Januari 2019 - Oktober 2021. Hasil penelitian didapatkan dari total 108 orang, terdapat 88 orang (81,48%) patuh pengobatan dan 20 orang (18,51%) tidak patuh pengobatan. Pasien patuh pengobatan memiliki karakteristik laki-laki sebanyak 53 orang (60,23%) berat badan tetap 86 orang (97,73%) dan usia rata-rata 37 tahun. Simpulan penelitian ini pasien patuh adalah Sebagian besar berjenis kelamin laki-laki, rata-rata berusia 37 tahun dan memiliki berat badan tetap paska pengobatan fase intensif. penelitian yang dilakukan oleh Heldiastri yang mengatakan bahwa tingkat kepatuhan pengobatan lebih banyak pada laki-laki, penelitian yang dilakukan oleh Friskilla bahwa pasien yang patuh dalam pengobatan adalah berumur 25-49 tahun dan penelitian yang dilakukan oleh Farroh Bintang yang menyatakan bahwa pada pasien yang menjalani pengobatan TB dengan patuh mengalami perbaikan dalam ukuran status gizi.

Hubungan antara Pemberian Remdesivir dan Durasi Rawat Inap Dibandingkan Favipiravir pada Pasien Covid-19 Alhilal Hamdi M.Nur; Heni Muflihah; Uci Ary Lantika
Bandung Conference Series: Medical Science Vol. 2 No. 1 (2022): Bandung Conference Series: Medical Science
Publisher : UNISBA Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/bcsms.v2i1.755

Abstarct. One of the pharmacological treatments for COVID-19 recommended by the World Health Organization (WHO) is remdesivir. Based on the Indonesian COVID-19 management manual, among the antivirals used are remdesivir and favipiravir. Remdesivir is indicated for severe patients, while favipiravir is indicated for moderate to severe patients. The selection of remdesivir or favipiravir based on clinical characteristics and benefits in COVID-19 patients in Indonesia has not been widely carried out. The benefits of pharmacological therapy in hospitalized COVID-19 patients can be seen, one of which is based on the duration of hospitalization. This study aimed to analyze the relationship between remdesivir use and duration of hospitalization compared to favipiravir in hospitalized COVID-19 patients. This study is a retrospective observational analytic study using medical record data. The subjects of this study were hospitalized COVID-19 patients at Al-Ihsan Hospital for the period December 2020 to March 2021. The data studied included clinical characteristics, oxygen saturation (SpO2), administration of remdesivir or favipiravir therapy, and duration of hospitalization. The subjects of this study were 102 people, consisting of 51 people in the remdesivir group and 51 people in the favipiravir group. Remdesivir is mostly given to patients aged > 50 years (72.5%) while favipiravir is mostly used in patients aged 18-50 years (53%). Severe grade patients (SpO2 <90%) had a median duration of hospitalization of 11 days, while non-severe patients (SpO2 >90%) had a median of 9 days. The remdesivir group had a median duration of hospital stay of 10 days while that of favipiravir was 11 days. Statistically there was no association between remdesivir administration and duration of hospitalization compared to favipiravir in COVID-19 patients (p-value = 0.2436). Remdesivir did not provide a clinical improvement in the duration of hospital stay when compared with favipiravir. Abstrak. Salah satu tatalaksana farmakologi COVID-19 yang dianjurkan World Health Organization (WHO) adalah remdesivir. Berdasarkan buku pedoman tatalaksana COVID-19 Indonesia, diantara antivirus yang digunakan adalah remdesivir dan favipiravir. Remdesivir diindikasikan untuk pasien derajat berat, sedangkan favipiravir untuk pasien derajat tidak berat sampai berat. Pemilihan jenis antivirus remdesivir atau favipiravir berdasarkan karakteristik klinis dan manfaatnya pada pasien COVID-19 di Indonesia belum banyak dilakukan. Manfaat terapi farmakologi pada pasien COVID-19 rawat inap dapat dilihat salah satunya berdasarkan durasi rawat inap. Penelitian ini bertujuan untuk menganalisis hubungan penggunaan remdesivir dan durasi rawat inap dibandingkan favipiravir pada pasien COVID-19 rawat inap. Penelitian ini merupakan penelitian analitik observasional retrospective menggunakan data rekam medik. Subyek penelitian ini adalah pasien COVID-19 rawat inap di RSUD Al-Ihsan periode Desember 2020 sampai Maret 2021. Data yang diteliti meliputi karakteristik klinis, saturasi oksigen (SpO2), pemberian terapi remdesivir atau favipiravir, dan durasi rawat inap. Subyek penelitian ini berjumlah 102 orang yang terdiri dari 51 orang kelompok terapi remdesivir dan 51 orang kelompok favipiravir. Remdesivir banyak diberikan pada pasien berusia > 50tahun (72.5%) sedangkan favipiravir banyak digunakan pada usia 18-50 tahun (53%). Pasien derajat berat (SpO2 <90%) memiliki durasi rawat inap dengan median 11 hari sedangkan pasien derajat tidak berat (SpO2 >90%) memiliki median 9 hari. Kelompok terapi remdesivir memiliki median durasi rawat inap 10 hari sedangkan favipiravir 11 hari. Secara statistik tidak terdapat hubungan antara pemberian obat remdesivir dan durasi rawat inap dibandingkan favipiravir pada pasien COVID-19 (p-value = 0.2436). Remdesivir tidak memberikan perbaikan klinis durasi raawat inap jika dibandingkan dengan favipiravir.

Hubungan Pemberian Remdesivir dengan Durasi Rawat Inap pada Pasien COVID-19 di Rumah Sakit Al-Islam Bandung Achmad Firar Khairi; Heni Muflihah; Meta Maulida Damayanti
Bandung Conference Series: Medical Science Vol. 2 No. 1 (2022): Bandung Conference Series: Medical Science
Publisher : UNISBA Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/bcsms.v2i1.784

Abstract. Coronavirus disease 2019 (COVID-19) is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which is a new type of corona virus. One of repurposive therapy recommended for COVID-19 patients is remdesivir. Few studies have examined the use of remdesivir as an anti-viral drug in Indonesia. The benefits of clinical improvement can be indicated by the length of stay (LOS). This study aims to analyze the relationship between remdesivir administration and the LOS in COVID-19 patients at Al-Islam Hospital Bandung. This study is an observational analytic study using a retrospective cohort design and medical record data. The subjects of the study were confirmed COVID-19 patients who were hospitalized at Al-Islam Hospital Bandung for the period June-July 2021. The data taken included clinical characteristics, oxygen saturation (SpO2), remdesivir therapy, and LOS using purposive sampling technique. The total study subjects were 111 patients consisting of 55 people in the remdesivir group and 56 people in the combination remdesivir comparison group. There were 50 patients (89%) in the remdesivir group (89%) and 40 people (71%). The remdesivir group was mostly female as many as 33 people (60%). LOS for men had a median of 9 days, 3 days longer than for women. LOS in the remdesivir group had a median of 5 (interquartile range (IQR) 3-12) days, while the combination remdesivir had a median of 9 (IQR 4-16) days which was statistically significant (P-value <0.0001). It can be concluded that there is a relationship between the administration of remdesivir and LOS of COVID-19 patients. The combination of remdesivir with other antivirals needs to be evaluated for indications considering that it does not increase the benefit of improving LOS. Abstrak. Coronavirus disease 2019 (COVID-19) merupakan penyakit infeksi yang disebabkan oleh Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) yang merupakan virus korona jenis baru. Diantara terapi repurposive yang direkomendasikan pada pasien COVID-19 salah satunya remdesivir. Belum banyak penelitian yang mengkaji penggunaan remdesivir sebagai obat anti virus di Indonesia. Salah satu indikator manfaat perbaikan klinis dapat dilihat berdasarkan durasi rawat inap. Tujuan penelitian menganalisis hubungan pemberian remdesivir dengan durasi lama rawat inap pada pasien COVID-19 di RS Al-Islam Bandung. Penelitian ini merupakan analitik observasional menggunakan desain kohort retrospektif dan data rekam medik. Subyek penelitian adalah pasien terkonfirmasi COVID-19 yang menjalani rawat inap di Rumah Sakit Al-Islam Bandung periode Juni-Juli 2021. Data yang diambil meliputi karakteristik klinis, saturasi oksigen (SpO2), terapi remdesivir, dan durasi rawat inap menggunakan teknik purposive sampling. Total subyek penelitian berjumlah 111 pasien terdiri dari 55 orang kelompok remdesivir dan 56 orang kelompok pembanding remdesivir kombinasi. Pasien COVID-19 derajat tidak berat (SpO2 90%) pada kelompok remdesivir sebanyak 50 orang (89%) dan remdesivir kombinasi 40 orang (71%). Kelompok remdesivir sebagian besar berjenis kelamin wanita sebanyak 33 orang (60%). Durasi rawat inap pria memiliki median 9 hari, 3 hari lebih lama dari wanita. Durasi rawat inap kelompok remdesivir memiliki median 5 (interquartile range (IQR) 3-12) hari, sedangkan remdesivir kombinasi memiliki median 9 (IQR 4-16) hari yang secara statistik berbeda bermakna (P-Value <0.0001). Dapat disimpulkan terdapat hubungan antara pemberian remdesivir dan durasi rawat inap pasien COVID-19. Kombinasi remdesivir dengan antivirus lain perlu dievaluasi indikasinya mengingat tidak menambah manfaat perbaikan durasi rawat inap.

Karakteristik Klinis dan Derajat Keparahan Pasien COVID-19 yang Menerima Azitromisin di RSUD Al-Ihsan Zacky Muttaqien; Heni Muflihah; Dadang Rukanta
Bandung Conference Series: Medical Science Vol. 2 No. 1 (2022): Bandung Conference Series: Medical Science
Publisher : UNISBA Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/bcsms.v2i1.941

Abstract. COVID-19 infect the respiratory tract, can be a predisposing factor for bacterial co-infection, which is can affect the severity to death. The antibiotics are given empirically, which is Azithromycin is often used for pneumonia indications. Azithromycin is macrolide antibiotic, effective against bacteria by inhibiting bacterial protein synthesis. Clinical characteristics and severity of COVID-19 can be an indication of taking Azithromycin. This research is aimed to describe the clinical characteristic and severity in the patients of COVID-19 taking Azithromycin. The research uses descriptive method with cross sectional approach. It uses the medical record of patients with confirmed COVID-19 hospitalized at the Al-Ihsan Hospital for the period August 2020 - March 2021. The sampling technique used was purposive sampling from medical record data with a total sample of 88 people who entered the inclusive criteria. The results of this research found that from the total of 88 subjects. Patients aged 18-60 years dominate 67 people (>75%) in Azithromycin groups. 46 people (52.27%) are severe COVID-19 (SpO2 ≤ 90%). Conclusion: The use of Azithromycin dominated age 18-60 years, had a comorbid condition and were used in patients with severe COVID-19 and non-severe COVID-19. Abstrak. Infeksi COVID-19 di saluran pernapasan dikatakan dapat menjadi faktor predisposisi dari ko-infeksi bakteri yang dapat berakibat buruk terhadap derajat keparahan hingga kematian. Pemberian antibiotik pada pasien COVID-19 secara empirik sering menggunakan obat dengan indikasi pneumonia seperti Azitromisin. Azitromisin adalah antibiotik golongan makrolida yang menghambat sintesis protein bakteri. Karakteristik klinis dan derajat penyakit dapat menjadi indikasi pemberian azitromisin. Tujuan penelitian ini adalah untuk mengetahui gambaran karakteristik klinis dan derajat keparahan pasien COVID-19 yang diberikan Azitromisin di RSUD Al-Ihsan, Bandung. Penelitian deskriptif ini menggunakan pendekatan cross sectional dan menggunakan data rekam medis pasien terkonfirmasi COVID-19 rawat inap di RSUD Al-Ihsan periode Agustus 2020 – Maret 2021. Sampel dilakukan dengan teknik purposive sampling. Total subjek penelitian 88 orang yang termasuk kriteria inklusi. Hasil penelitian menggambarkan pasien yang mendapatkan Azitromisin ini sebanyak 67 orang (76.13%) berusia 18-60 tahun dan 53 orang (48.76%) memiliki komorbid. Sebanyak 46 orang (52.27%) penerima Azitromisin memiliki COVID-19 derajat berat (SpO2 ≤ 90%). Kesimpulan: Pemberian Azitromisin didominasi karakteristik usia 18-60 tahun, dan memiliki komorbid. Terapi Azitromisin diberikan pada pasien dengan derajat COVID-19 tidak berat dan berat.

Hubungan Pemberian Metilprednisolon dan Tocilizumab pada Pasien Covid-19 di Rumah Sakit Al Islam Bandung Zetananda Kirana Fauziyah Dakirun; Heni Muflihah; Endang Suherlan
Bandung Conference Series: Medical Science Vol. 2 No. 1 (2022): Bandung Conference Series: Medical Science
Publisher : UNISBA Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/bcsms.v2i1.1906

Abstract. Corona Virus Disease (COVID-19) is a pandemic that has spread to Indonesia. West Java is the province with the second-highest number of COVID-19 cases. Immunomodulators are recommended in COVID-19 patients, with inconsistent benefits across studies. Methylprednisolone acts non-specifically, while tocilizumab acts specifically at the IL-6 receptor. One indication of the administration of immunomodulators is the severity of COVID-19. This study was conducted to determine the relationship between administration of methylprednisolone and tocilizumab with the severity in hospitalized COVID-19 patients at Al Islam Hospital Bandung (RSAI). This study is an analytic observational with cross-sectional approach and uses medical records. The subjects of this study were confirmed COVID-19 patients who were hospitalized at Al Islam Hospital Bandung span from December 2020 until June 2021. The medical records were analyzed including oxygen saturation (SpO2) and administration of methylprednisolone or tocilizumab during hospitalization. Total research subjects are 116 people, consist of 31 people (59,61%) received methylprednisolone and 35 people (54,68%) received tocilizumab. There were 50 people (43,1%) had severe COVID-19 (SpO2 < 90%) and 66 people (56,9%) had non-severe COVID-19 (SpO2 90%). There was no relationship between the administration of methylprednisolone or tocilizumab with the severity of COVID-19 (p = 0,766). No relationship found between the selection of immunomodulators, methylprednisolone or tocilizumab with severity of COVID-19. Further research is needed to examine clinical conditions other than oxygen saturation to determine the severity COVID-19 disease in order to evaluate more accurately indications for immunomodulatory therapy. Abstrak. Corona Virus Disease (COVID-19) merupakan pandemi yang menyebar ke Indonesia. Jawa Barat adalah Provinsi dengan kasus COVID-19 kedua terbanyak. Imunomodulator direkomendasikan pada pasien COVID-19, dengan manfaat yang tidak konsisten di berbagai hasil penelitian. Metilprednisolon bekerja secara non-spesifik, sedangkan tocilizumab bekerja secara spesifik pada reseptor IL-6. Salah satu indikasi pemberian imunomodulator adalah derajat penyakit COVID-19. Penelitian ini dilakukan untuk mengetahui hubungan pemberian metilprednisolon dan tocilizumab dengan derajat penyakit pada pasien COVID-19 rawat inap di Rumah Sakit Al Islam Bandung (RSAI). Penelitian ini berupa observasional analitik dengan pendekatan cross sectional dan menggunakan data rekam medis. Subjek penelitian ini adalah pasien terkonfirmasi COVID-19 yang dirawat inap di RSAI pada periode Desember 2020 – Juni 2021. Data rekam medik yang dianalisis meliputi saturasi oksigen (SpO2) dan pemberian metilprednisolon atau tocilizumab selama dirawat. Total subyek penelitian berjumlah 116 orang. Jumlah ini terdiri dari 31 orang (59,61%) mendapat metilprednisolon dan 35 orang (54,68%) mendapat tocilizumab. Terdapat 50 orang (43,1%) memiliki derajat berat (SpO2 < 90%) dan 66 orang (56,9%) derajat tidak berat (SpO2 ≥ 90%). Tidak terdapat hubungan antara pemberian metilprednisolon atau tocilizumab dengan derajat penyakit (p = 0,766). Tidak terdapat hubungan pemilihan imunomodulator, metilprednisolon atau tocilizumab dengan derajat penyakit COVID-19. Penelitian lanjutan perlu menkaji kondisi klinis selain saturasi oksigen untuk penentuan derajat penyakit COVID-19 agar lebih tepat mengevaluasi indikasi terapi imunomodulator.

Pelatihan Liquid Soap Education dalam Upaya Memerangi Covid-19 Menuju Pencegahan Big Cluster di Pondok Pesantren Madania Yogyakarta Yani Triyani; Heni Muflihah; Mirasari Putri; Winni Maharani
ETHOS (Jurnal Penelitian dan Pengabdian) Vol 10 No.2 (Juni, 2022) Ethos: Jurnal Penelitian Dan Pangabdian Kepada Masyarakat (Sains & Teknolog
Publisher : Universitas Islam Bandung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/ethos.v10i2.8385

Abstract. The corona virus has increased and spread massively throughout the world, so it is called a pandemic. Indonesia is one of the areas that has been affected by this pandemic with the first case found on March 2, 2020. During the COVID-19 Pandemic, the Modern Islamic Boarding School, Madania as an orphanage that accommodates assisted occupants took step not to repatriate all occupants. Therefore, further steps need to be taken to overcome and prevent the spread of the corona virus pandemic in this Islamic boarding school. This study aims to determine the effect of empowerment and training on liquid soap education in the effort to fight against COVID-19. The research uses qualitative methods with data collected by sampling that use random samples through google form on the students of Madania Boarding School Yogyakarta. This training is done directly with keep obeying the health protocols. The result of this research is that with this training, the students of Madania Islamic Boarding School Yogyakarta can understand and practice independently to make liquid soap. Santri at Madania Islamic Boarding School Yogyakarta can improve their knowledge and skills in making liquid soap to prevent the Corona Virus from spreading in the Islamic boarding school environment.Abstrak. Virus corona meningkat dengan penyebaran masif sebagai pandemi. Indonesia termasuk wilayah yang terjangkit dengan kasus pertama yang ditemukan pada 2 Maret 2020. Masa Pandemi COVID-19 Pondok Pesantren Modern Yatim Piatu Dhuafa Madania sebagai panti asuhan yang menampung warga binaan mengambil langkah tidak memulangkan seluruh warga binaan. Pemberdayaan dan pelatihan perlu dilakukan langkah untuk menanggulangi penyebaran pandemi corona di dalam internal pondok pesantren. Penelitian ini bertujuan mengetahui pengaruh pemberdayaan dan pelatihan soap liquid education dalam upaya memerangi COVID-19. Metode penelitian menggunakan metode kualitatif dengan teknik pengambilan data secara sampling acak melalui google form pada santri Pondok Pesantren Madania Yogyakarta. Pelatihan ini dilakukan secara langsung dengan tetap mematuhi protokol kesehatan. Dari Hasil penelitian dengan adanya pelatihan ini, santri Pondok Pesantren Madania Yogyakarta dapat mengetahui dan mempraktikan secara mandiri pembuatan sabun cair. Santri dapat meningkatkan pengetahuan dan keterampilan membuat sabun cair untuk mencegah Virus Corona menyebar di lingkungan Pondok Pesantren tersebut.

Hubungan Karakteristik Penderita Tuberkulosis Paru dengan Hasil Pemeriksaan Tes Cepat Molekuler (TCM) Siti Rimayah; Heni Muflihah; Tety H Rahim
Bandung Conference Series: Medical Science Vol. 3 No. 1 (2023): Bandung Conference Series: Medical Science
Publisher : UNISBA Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/bcsms.v3i1.6666

Abstract. Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis (MTB). The spread of MTB through the air is related to people's activities according to age, gender and occupation. The diagnosis of TB is currently enforced by the Molecular Rapid Test (TCM) method which replaces the microscopic examination of Acid-Fast Bacilli (AFB). The purpose of this study was to determine the relationship between the characteristics of pulmonary TB sufferers and the results of the TCM examination. This research is an analytic observational using secondary data. The subjects of this study were pulmonary TB patients at the Kertasemaya Health Center in the period January 2020 to December 2022. The research data included age, gender, occupation and TCM results. Analysis of the relationship between variables using the Chi-square test. A total of 100 subjects who met the inclusion criteria were patients diagnosed with pulmonary TB, the characteristics and results of TCM were recorded in medical records, and the age of the patient was over 15 years. The main characteristics of pulmonary TB sufferers are productive age (15-50 years) totaling 70 people (70%), male gender numbering 64 people (64%) and the majority not working totaling 57 people (57%). There was no relationship between age and TCM results (p=0.571), gender and TCM results (p=0.546), and occupation and TCM results (p=1.000). The conclusion of this study is that there is no relationship between age, gender, and occupation with the TCM examination results in pulmonary TB patients. Keywords: Age, Gender, Occupation, Pulmonary TB, TCM Abstrak. Tuberkulosis (TB) merupakan penyakit yang disebabkan Mycobacterium tuberculosis (MTB). Penyebaran MTB melalui udara berkaitan dengan aktivitas orang sesuai dengan usia, jenis kelamin, dan pekerjaan. Diagnosis TB saat ini ditegakkan dengan metode Test Cepat Molekuler (TCM) yang menggantikan pemeriksaan mikroskopik Basil Tahan Asam (BTA). Tujuan penelitian ini yaitu untuk mengetahui hubungan karakteristik penderita TB Paru dengan hasil pemeriksaan TCM. Penelitian merupakan observasional analitik menggunakan data sekunder. Subjek penelitian ini adalah pasien TB Paru di Puskesmas Kertasemaya pada periode Januari 2020 sampai Desember 2022. Data penelitian meliputi usia, jenis kelamin, pekerjaan serta hasil TCM. Analisis hubungan antar variabel menggunakan uji Chi-square. Total subjek berjumlah 100 orang yang memiliki kriteria inklusi yaitu pasien terdiagnosis TB Paru, Karakteristik dan hasil TCM tercatat rekam medis, dan usia penderita di atas 15 tahun. Karakteristik utama penderita TB Paru adalah berusia produktif (15 – 50 tahun) berjumlah 70 orang (70%), jenis kelamin laki – laki berjumlah 64 orang (64%) dan mayoritas tidak bekerja berjumlah 57 orang (57%). Tidak ada hubungan antara usia dengan hasil TCM (p=0,571), jenis kelamin dengan hasil TCM (p=0,546), dan pekerjaan dengan hasil TCM (p=1,000). Kesimpulan penelitian ini adalah tidak terdapat hubungan antara usia, jenis kelamin, dan pekerjaan dengan hasil pemeriksaan TCM pada penderita TB paru. Kata Kunci: Jenis Kelamin, Pekerjaan, TCM, TB Paru, Usia

Hipertensi sebagai Komorbid Tunggal Merupakan Faktor Risiko Kematian COVID-19: Case-Control Study Zenia Salha; Endang Suherlan; Heni Muflihah
Bandung Conference Series: Medical Science Vol. 3 No. 1 (2023): Bandung Conference Series: Medical Science
Publisher : UNISBA Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/bcsms.v3i1.6966

Abstract. The mortality of Coronavirus Disease 2019 (COVID-19) is associated with elderly age, gender, and comorbid hypertension. Studies examining the relationship between comorbid hypertension and COVID-19 mortality by controlling for age and gender is limited. This study aimed to analyze hypertension as a risk factor for the mortality of COVID-19 by controlling age and gender. This case-control study medical records. The subjects were confirmed COVID-19 patients who were hospitalized at dr. Slamet Garut period December 2020 – December 2021. The case group was COVID-19 patients who died following hospitalisation. The control group was survived COVID-19 patients who were individually matched with the case group in the age and sex. Comorbid hypertension is hypertension was defined as alone without other comorbidities. A total of 322 subjects consisting of 161 patients in the case group and 161 patients in the control group. In the case group, 151 patients (93.8%) were elderly people, 83 patients (51.5%) were female, and 87 patients (54%) had comorbid hypertension. Comorbid hypertension was present in 87 people (54.0%) of the case group dan 24 people (14.9%) of the control. Hypertension has a significant relationship with the mortality of COVID-19 (p=0.000) with OR 6.711. This study concludes that COVID-19 patients with hypertension as a single comorbid have a 6 times higher risk of death than patients in the same age and sex. Abstrak. Kematian Coronavirus Disease 2019 (COVID-19) berhubungan dengan usia lansia, jenis kelamin, dan komorbid hipertensi. Penelitian yang mengkaji hubungan hipertensi dengan kematian COVID-19 dengan mengendalikan faktor usia dan jenis kelamin masih jarang. Penelitian ini bertujuan menganalisis faktor resiko hipertensi pada kematian COVID-19 dengan mengendalikan usia dan jenis kelamin. Penelitian case control ini menggunakan rekam medis. Subjek penelitian adalah pasien terkonfirmasi COVID-19 yang dirawat inap di RSUD dr. Slamet Garut periode Desember 2020 – Desember 2021. Kelompok case adalah pasien COVID-19 yang meninggal. Kelompok control adalah pasien COVID-19 tidak meninggal yang sesuai usia dan jenis kelamin pada setiap subjek (individual matched) kelompok case. Komorbid hipertensi didefinisikan penyakit hipertensi saja tanpa disertai komorbid lain. Subjek penelitian berjumlah 322 orang yang terdiri dari 161 kelompok case dan 161 kelompok control. Pasien COVID-19 meninggal berusia lansia sebanyak 151 orang (93.8%), perempuan 83 orang (51.5%) dan memiliki komorbid hipertensi 87 orang (54%). Komorbid hipertensi pada kelompok case sebanyak 87 orang (54.0%), sedangkan kelompok control 24 orang (14.9%). Hipertensi memiliki hubungan dengan kematian COVID-19 secara signifikan (p=0.000) dengan OR 6.711. Kesimpulan penelitian ini pasien COVID-19 adalah komorbid tunggal hipertensi memiliki resiko 6 kali lebih tinggi untuk meninggal dibandingkan pasien lain pada usia dan jenis kelamin sama.

Hipertensi Sebagai Komorbid Tunggal Merupakan Faktor Risiko Kematian COVID-19: Case-Control Study Zenia Salha; Heni Muflihah; Endang Suherlan
Bandung Conference Series: Medical Science Vol. 3 No. 1 (2023): Bandung Conference Series: Medical Science
Publisher : UNISBA Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/bcsms.v3i1.6975

Abstract. The mortality of Coronavirus Disease 2019 (COVID-19) is associated with elderly age, gender, and comorbid hypertension. Studies examining the relationship between comorbid hypertension and COVID-19 mortality by controlling for age and gender is limited. This study aimed to analyze hypertension as a risk factor for the mortality of COVID-19 by controlling age and gender. This case-control study medical records. The subjects were confirmed COVID-19 patients who were hospitalized at dr. Slamet Garut period December 2020 – December 2021. The case group was COVID-19 patients who died following hospitalisation. The control group was survived COVID-19 patients who were individually matched with the case group in the age and sex. Comorbid hypertension is hypertension was defined as alone without other comorbidities. A total of 322 subjects consisting of 161 patients in the case group and 161 patients in the control group. In the case group, 151 patients (93.8%) were elderly people, 83 patients (51.5%) were female, and 87 patients (54%) had comorbid hypertension. Comorbid hypertension was present in 87 people (54.0%) of the case group dan 24 people (14.9%) of the control. Hypertension has a significant relationship with the mortality of COVID-19 (p=0.000) with OR 6.711. This study concludes that COVID-19 patients with hypertension as a single comorbid have a 6 times higher risk of death than patients in the same age and sex. Abstrak. Kematian Coronavirus Disease 2019 (COVID-19) berhubungan dengan usia lansia, jenis kelamin, dan komorbid hipertensi. Penelitian yang mengkaji hubungan hipertensi dengan kematian COVID-19 dengan mengendalikan faktor usia dan jenis kelamin masih jarang. Penelitian ini bertujuan menganalisis faktor resiko hipertensi pada kematian COVID-19 dengan mengendalikan usia dan jenis kelamin. Penelitian case control ini menggunakan rekam medis. Subjek penelitian adalah pasien terkonfirmasi COVID-19 yang dirawat inap di RSUD dr. Slamet Garut periode Desember 2020 – Desember 2021. Kelompok case adalah pasien COVID-19 yang meninggal. Kelompok control adalah pasien COVID-19 tidak meninggal yang sesuai usia dan jenis kelamin pada setiap subjek (individual matched) kelompok case. Komorbid hipertensi didefinisikan penyakit hipertensi saja tanpa disertai komorbid lain. Subjek penelitian berjumlah 322 orang yang terdiri dari 161 kelompok case dan 161 kelompok control. Pasien COVID-19 meninggal berusia lansia sebanyak 151 orang (93.8%), perempuan 83 orang (51.5%) dan memiliki komorbid hipertensi 87 orang (54%). Komorbid hipertensi pada kelompok case sebanyak 87 orang (54.0%), sedangkan kelompok control 24 orang (14.9%). Hipertensi memiliki hubungan dengan kematian COVID-19 secara signifikan (p=0.000) dengan OR 6.711. Kesimpulan penelitian ini pasien COVID-19 adalah komorbid tunggal hipertensi memiliki resiko 6 kali lebih tinggi untuk meninggal dibandingkan pasien lain pada usia dan jenis kelamin sama.

Title

Found 13 Documents
Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title Search

Found 13 Documents Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title

Found 13 Documents
Search